Petition Closed
Petitioning Memorial Sloan-Kettering Cancer Center Craig B. Thompson, MD

We kindly request that Memorial Sloan-Kettering Cancer Center acknowledge their positive results with laetrile in the 1970s.

Forty years ago this summer (1974) Ralph W. Moss, PhD was hired at Memorial Sloan-Kettering Cancer Center (MSKCC) to be its science writer in the Department of Public Affairs. The “war on cancer” was new, and MSKCC, under the direction of Drs. Lewis Thomas, Robert A. Good and Lloyd J. Old had been revitalized to face the challenges of the day.

The “war on cancer” meant a fresh infusion of vast amounts of cash and new leadership that had direct access to the President of the United States in order to expedite promising treatments. The leaders of the “war on cancer” actually promised the American public a “cure” for some major forms of cancer in time for the Bicentennial—July 4, 1976.

There was a renewed interest in various unorthodox methods of treating cancer. Public interest gravitated towards an unorthodox treatment called laetrile. This was an extract of apricot kernels, synonymous with a well-known cyanide-containing chemical, amygdalin.

Responding to a petition from 43,000 supporters of the drug, the US “cancer czar” Benno Schmidt asked MSKCC’s leaders to test the drug competently and fairly. They therefore asked the oldest and most experienced researcher, Kanematsu Sugiura, DSc, to test laetrile in various spontaneous tumor systems. The results were overwhelmingly positive. Over the course of five years, Sugiura found that laetrile exerted a profoundly beneficial effect not just on the health and well being of the mice but on stopping lung metastases. MSKCC’s pathology department confirmed his positive findings.

Initially, the leadership of MSKCC affirmed Sugiura’s findings. Then they began to backtrack in public. In 1974 the American Cancer Society (ACS), threatened Dr. Good to back off from laetrile. Behind the scenes, Old tried to uphold Sugiura’s findings. But they did not win over their colleagues at the National Cancer Institute, the Food and Drug Administration or the American Cancer Society. At this moment, MSKCC leaders (and in particular Lewis Thomas) decided that the cause was hopelessly dangerous to himself and to his institution and so within weeks went over to the anti-laetrile camp. Thomas wound up as a key witness against laetrile at Sen. Kennedy’s hearings on the topic in 1977, lying about Sugiura’s results with a straight face.

Eventually, the leadership issued an entirely negative summation of the laetrile testing program. (Ralph W. Moss, PhD himself wrote the official press release). Ralph started a newsletter called “Second Opinion” to publicize the problems and contradictions in MSKCC’s official pronouncements. In November 1977 Ralph went public with these accusations and was fired on the next business day for failing to carry out his “most basic job responsibilities.” Ralph W. Moss, PhD also wrote his first book, The Cancer Industry, about this and other cover-ups in the cancer research and treatment field. Yet for many years Ralph has let the matter rest. Why then bring it up now?

First of all, a new generation of Americans, including most researchers, knows nothing about this controversy. Some of them were not even born when these events took place. Second, a terrible wrong was done to the reputation of one of MSKCC’s greatest scientists, Kanematsu Sugiura. For the sake of political expediency Sugiura was “thrown under the bus,” as we now would say. But, most importantly, pure amygdalin was an extremely promising anti-metastatic agent. It was certainly the most effective such agent discovered up until that time. To this day, if there are any better agents that have been proven as effective at preventing the spread of cancer they are unknown to the public.

While progress has been made in understanding cancer in the past 40 years, effective treatments for preventing the spread of cancer are still few and far between. Laetrile was a lost opportunity—killed off in a cynical way. Unfortunately, the outstanding experimental results of Sugiura became the victim of a highly politicized vendetta.

Above all, we would urge MSKCC to reconsider its handling of the laetrile controversy. The facts, when considered without bias, show that Sugiura was both competent and honest, while those who were in power at the time lost their nerve and compromised the truth in a very shameful way.

Sept 2, 2014 UPDATE: Top researchers in Germany have just confirmed the efficacy of Laetrile/Anygmalin in lab tests. Published in the peer-reviewed literature, click here to read

More info and sources: 

1. June 2, 1974 "Minutes" with the leaders of Sloan-Kettering and the FDA discussing Dr. Sugiura's positive Laetrile (amygdalin) experiments and the need to graduate their research into human clinical trials. (obtained via FOIA) 

2. Sloan-Kettering's lab studies conducted by Dr. Kanematsu Sugiura - leaked by "Second Opinion".

3. The "Second Opinion Special Report: Laetrile At Sloan-Kettering" 

4. Handwritten letter from Dr. Kanematsu Sugiura to "Second Opinion" commending them on their "Special Report" exposing the details of how Sloan-Kettering manipulated their positive Laetrile data. 

5. Dr. Kanematsu Sugiura's obituary published in "Cancer Research". 

6. www.mskcc-please-respond.org

7. August 19, 2014 Laetrile/amygdalin peer-reviewed study, "Amygdalin Blocks Bladder Cancer Cell Growth"

This petition was delivered to:
  • Memorial Sloan-Kettering Cancer Center
    Craig B. Thompson, MD


    Second Opinion started this petition with a single signature, and now has 12,256 supporters. Start a petition today to change something you care about.




    Today: Second is counting on you

    Second Opinion needs your help with “Requesting that Sloan-Kettering Cancer Center acknowledge their positive Laetrile studies.”. Join Second and 12,255 supporters today.